Article Text

Download PDFPDF
Letter
Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer’s disease

Statistics from Altmetric.com

Footnotes

  • Twitter @JenniferGatchel, @ytquiroz

  • Presented at Preliminary findings related to a subset of the data in the manuscript were presented at the 2017 Alzheimer’s Association International Conference.

  • Correction notice This paper has been corrected since it was published online first. Author name has been corrected from "Frederico" to "Federico".

  • Contributors The first (JRG) and senior (YTQ) authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design: JRG, GAM, FL, YTQ. Study supervision: JRG, GAM, FL, YTQ. Acquisition of data: FL, EGV, AA, DJN, AB, YTQ. Analysis and interpretation of data: JRG, GAM, FL, AB, DJN, EGV, JSS, FdOU, AS, PV, REA, DMR, PNT, EMR, KAJ, REA, YTQ. Statistical analysis: JRG, DJN, JSS, FdOU, YTQ. Drafting the manuscript: JRG, GAM, DJN, FL, PNT, EMR, YTQ. Preparation of figures and tables: JRG, JSS. Critical revision of the manuscript for important intellectual content: JRG, FL, DJN, AB, EGV, JSS, FdOU, AS, PV, AA, REA, DMR, PNT, EMR, KAJ, REA, GAM, YTQ.

  • Funding This work was supported by the NIH Office of the Director (DP5OD019833 to YTQ); NIH/NIA (R01AG054671 to YTQ); and the Massachusetts General Hospital ECOR (1200-228010 and 1200-228767 to YTQ). JRG is supported by NIH/NIA (K23 AG058805-01); the Alzheimer’s Association (AACF_16-440965); the BrightFocus Foundation (ADRF A2016434F); and the Massachusetts General Hospital Rappaport Fellowship.

  • Competing interests FL is supported by a grant to the Alzheimer’s Prevention Initiative (API) Colombia, funded by Genentech and Banner Alzheimer’s Institute in Arizona. PNT has received consulting fees from Acadia, Abbott Laboratories, AbbVie, AC Immune, Auspex, Boehringer Ingelheim, Chase Pharmaceuticals, Eisai, GliaCure, Insys Therapeutics and Pfizer. He has received consulting fees and research support from AstraZeneca, Avanir, Eli Lilly, Lundbeck, Merck & Co, Roche, and research support only from Amgen, Avid, Biogen, Elan, Functional Neuromodulation (f[nm]), GE Healthcare, Genentech, Novartis and Targacept. PNT has received other research support from the National Institute on Aging and Arizona Department of Health Services and holds stock options in ADAMAS. EMR has received research support from the National Institute on Aging, Novartis/Amgen, Banner Alzheimer's Foundation, Alzheimer's Association, GHR Foundation, F-Prime Biosciences Research Initiative and NOMIS Foundation. He also reports that he is a compensated scientific advisor with Alkahest, Alzheon, Axovant, Denali, Green Valley, United Neuroscience and Zinfandel Pharma. Banner Alzheimer's Institute has contracts with Genentech/Roche, Novartis/Amgen and Avid/Lilly. DMR has served as a consultant for Eli Lilly, Neurotrack and Lundbeck. KAJ has received salary support from Avid Radiopharmaceuticals, and served as a consultant for Eli Lilly, Novartis, Janssen, Roche, Piramal, GE Healthcare, Siemens, ISIS Pharma, AZTherapy and Biogen. RAS has received salary support from Eli Lilly and Janssen Alzheimer Immunotherapy and has served as a consultant for AbbVie, Biogen, Bracket, Genentech, Lundbeck, Merck, Pfizer, Roche and Sanofi. GAM received research salary support from Eisai, Eli Lilly, Janssen Alzheimer Immunotherapy, Novartis and Genentech. He also has served as a consultant for Eisai, Grifols Shared Services North America and Pfizer.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.